A multicentre study to assess prognostic performance and optimal timing for sampling within the peri- and post-discharge period of recently discovered promising Heart Failure biomarkers for indication of 30, 90, 180 days and 1 year prognosis.

niversity of Otago, Christchurch0 sites450 target enrollmentJanuary 21, 2015

Overview

No summary available.

Registry

who.int

Start Date

January 21, 2015

End Date

TBD

Last Updated

4 years ago

Study Type

Observational

Sex

All

Sponsor

niversity of Otago, Christchurch

•1\.Patients aged \>18 year,
•2\.Admitted with ADHF as evidenced by typical clinical features plus either radiological evidence of HF or an NTproBNP level \>1000pg/ml (120 pmol/L).

•1\.A primary diagnosis of either acute coronary syndrome (ACS), myocarditis/pericarditis, pericardial constriction or AF with rapid ventricular rate
•2\.Severe valvular disease requiring surgery, severe aortic stenosis (valve area \<1 cm^2\), or HF due to mitral stenosis
•3\.Under consideration for cardiac transplantation
•4\.Currently enrolled in other interventional or therapeutic heart failure trial.
•5\.Life expectancy due to non\-cardiac disease of \<6 months
•6\.Concurrent severe hepatic disease (determined by investigator)
•7\.Concurrent severe pulmonary disease (FEV1\<1 L)
•8\.Severe renal impairment (plasma creatinine \>250 micromol/L, EGFR \< 15mls/min) or receiving renal replacement therapy.
•9\.Unwilling or unable to consent
•10\.Unable to comply with study protocol (e.g. out of town)